MVA member Genmab wins Biotechnology's Helix Award for top performance

Genmab A/S recently announced it has won the James D. Watson Helix Award in the international category.The Helix Award honors biotechnology companies that display leadership in three areas:scientific innovation, company growth and corporate citizenship. Winners are selected by peer vote and the award was presented February 24 at the BIO CEO and Investor Conference in New York.

Genmab was honored for its significant advances during 2004 that included the presentation of positive data from all five of its clinical programs: Phase II proof of concept data for two products, HuMax-CD4 and the Amgen partnered AMG-714, and promising Phase I/II data for HuMax-CD20, HuMax-EGFr and HuMax-Inflam.Genmab also received Fast Track designations for HuMax-CD4 and HuMax-CD20 from the FDA and obtained two Orphan Drug designations.In the financial area, the company raised a total of approximately DKK 542 million (approximately US$100 million), primarily through a successful follow on offering, and the company’s stock price appreciated by 96% during the year.

“With the Helix Award, Genmab’s peers recognized the company’s recent record of success,” said BIO President Jim Greenwood."Genmab is realizing the goal of hundreds of fellow biotechnology firms by translating platform technologies into a diverse pipeline of promising clinical-stage products to address unmet medical needs.”

“The entire Genmab team worked with great dedication to achieve the milestones that led to the Helix Award. We are honored by the award and the recognition of our efforts by our peers. This will spur us on in our quest to bring important new treatments to the patients who are waiting for them,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

The award was presented by the Long Island Life Sciences Initiative and is jointly sponsored by the Biotechnology Industry Organization, Stony Brook University and The Center for Biotechnology.

Genmab is a member of Medicon Valley Academy / More information: www.genmab.com